ROCKVILLE, Md., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its third quarter financial results for the three-month period ended September 30, 2012. The Company reported a net loss of $4.1 million, or $0.12 per share, compared to net income of $0.1 million, or zero per share, for the prior year period.
